A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival

Breast cancer ranks first in terms of mortality and incidence rates worldwide among women. The HER2+ molecular subtype is one of the most aggressive subtypes; its treatment includes neoadjuvant chemotherapy and the use of a HER2 antibody. Some patients develop resistance despite positive results obt...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrón-Gallardo, Carlos A., Garcia-Chagollán, Mariel, Morán-Mendoza, Andres J., Delgadillo-Cristerna, Raul, Martínez-Silva, María G., Villaseñor-García, María M., Aguilar-Lemarroy, Adriana, Jave-Suárez, Luis F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634254/
https://www.ncbi.nlm.nih.gov/pubmed/36338974
http://dx.doi.org/10.3389/fgene.2022.991706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634254/
https://www.ncbi.nlm.nih.gov/pubmed/36338974
http://dx.doi.org/10.3389/fgene.2022.991706

Ejemplares similares